We are live on ! Find out more
AKBA icon

Akebia Therapeutics
AKBA

150 hedge funds and large institutions have $334M invested in Akebia Therapeutics in 2019 Q3 according to their latest regulatory filings, with 20 funds opening new positions, 44 increasing their positions, 44 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,023% more call options, than puts

Call options by funds: $19.3M | Put options by funds: $468K

0% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 44

1% less funds holding

Funds holding: 151 → 150 (-1)

5% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 21

2.05% less ownership

Funds ownership: 73.76% → 71.7% (-2.1%)

21% less capital invested

Capital invested by funds: $421M → $334M (-$86.5M)

Holders
150
Holders Change
-1
Holders Change %
-0.66%
% of All Funds
3.29%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
44
Reduced
44
Closed
21
Calls
$19.3M
Puts
$468K
Net Calls
+$18.8M
Net Calls Change
-$4.86M

Top Buyers

Rank Fund Capital Flow
1
SI
Sofinnova Investments
California
+$1.62M
2
BlackRock
BlackRock
New York
+$1.51M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.27M
4
Northern Trust
Northern Trust
Illinois
+$1.21M
5
Citadel Advisors
Citadel Advisors
Florida
+$1.15M

Top Sellers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
-$9.23M
2
Man Group
Man Group
United Kingdom
-$2.44M
3
OWIM
Old West Investment Management
California
-$935K
4
Morgan Stanley
Morgan Stanley
New York
-$809K
5
Bank of America
Bank of America
North Carolina
-$785K
Name Holding Trade Value Shares
Change 		Change in
Stake
First Manhattan
51
First Manhattan
New York
$485K +$531K +123,900 New
AllianceBernstein
52
AllianceBernstein
Tennessee
$481K – – –
New York State Common Retirement Fund
53
New York State Common Retirement Fund
New York
$475K – – –
Barclays
54
Barclays
United Kingdom
$467K -$45.5K -10,615 -8%
Fidelity Investments
55
Fidelity Investments
Massachusetts
$420K -$163K -38,074 -26%
CAM
56
ClariVest Asset Management
California
$391K -$3.86K -900 -0.9%
FP
57
Foundry Partners
Minnesota
$364K -$934 -218 -0.2%
OAM
58
Oxford Asset Management
United Kingdom
$359K -$130K -30,445 -25%
AQR Capital Management
59
AQR Capital Management
Connecticut
$352K +$337K +78,575 +702%
BGIM
60
Brandywine Global Investment Management
Pennsylvania
$329K -$65.2K -15,213 -15%
UBS AM
61
UBS AM
Illinois
$315K +$23.5K +5,478 +7%
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$309K – – –
JIC
63
Johnson Investment Counsel
Ohio
$298K – – –
AIG
64
American International Group
New York
$292K -$2.23K -520 -0.7%
William Blair & Company
65
William Blair & Company
Illinois
$288K -$8.57K -2,000 -3%
CM
66
Caption Management
Oklahoma
$288K – – –
BFM
67
Boothbay Fund Management
New York
$278K +$304K +71,000 New
Group One Trading
68
Group One Trading
Illinois
$267K -$8.68K -2,025 -3%
VEA
69
Virtus ETF Advisers
New York
$242K -$14.7K -3,433 -5%
MIM
70
MetLife Investment Management
New Jersey
$225K – – –
Millennium Management
71
Millennium Management
New York
$190K -$546K -127,501 -72%
SO
72
STRS Ohio
Ohio
$187K – – –
Deutsche Bank
73
Deutsche Bank
Germany
$180K -$443K -103,402 -69%
ProShare Advisors
74
ProShare Advisors
Maryland
$179K +$9.13K +2,131 +5%
Renaissance Technologies
75
Renaissance Technologies
New York
$170K +$186K +43,427 New
1 2
3
4 5

AKBA Hedge Fund Activity: Q3 2019 in Review

150 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Akebia Therapeutics (AKBA) for Q3 2019, worth a combined $334M — down 21% from $421M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of AKBA and 20 opened new positions — a net loss of 1 holder — while 44 trimmed existing stakes and 44 added.

The largest buyer was Sofinnova Investments, adding an estimated $1.62M. The largest seller was State Street, cutting an estimated $9.23M.

  • 150 institutional investors held Akebia Therapeutics (AKBA) as of Q3 2019, down from 151 in Q2 2019.
  • Funds reported $334M of Akebia Therapeutics stock for Q3 2019, down 21% quarter-over-quarter.
  • 20 funds opened new Akebia Therapeutics positions in Q3 2019 and 21 closed out, a net change of -1 holder.
  • The largest Akebia Therapeutics buyer in Q3 2019 was Sofinnova Investments, an estimated $1.62M added.
  • The largest Akebia Therapeutics seller in Q3 2019 was State Street, an estimated $9.23M sold.

Based on aggregated 13F filings for Q3 2019.